Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 2, 2003, Pages 725-732

  Bergamo, Alberta ^a   Stocco, Gabriele ^a   Gava, Barbara ^a   Cocchietto, Moreno ^a   Alessio, Enzo ^b   Serli, Barbara ^b   Iengo, Elisabetta ^c   Sava, Gianni ^a,b  

^a Callerio Foundation   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Laboratories for Biological Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; IMIDAZOLE DERIVATIVE; RUTHENIUM COMPLEX;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ACTIVITY; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; KB CELLS; MELANOMA, EXPERIMENTAL; MICE; RATS; RUTHENIUM; SPECTROPHOTOMETRY, ATOMIC; TUMOR CELLS, CULTURED;

EID: 0037405663     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.047803     Document Type: Article

References (40)

1. 2(μ-L)] (L = ditopic, non-chelating aromatic N-ligand). A preliminary investigation. J Inorg Biochem 79:173-177.
2. Barca A, Pani B, Tamaro M, and Russo E (1999) Molecular interactions of ruthenium complexes in isolated mammalian cells and cytotoxicity on V79 cell in culture. Mutat Res 423:171-181.
3. Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, and Sava G (1999) In vitro cell cycle arrest, in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 289:559-564.
4. Bergamo A, Gava B, Alessio E, Mestroni G, Serli B, Cocchietto M, Zorzet S, and Sava G (2002) Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int J Oncol 21:1331-1338.
5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. 2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91:164-173.
7. Clarke MJ (1989) Ruthenium chemistry pertaining to the design of anticancer agents, in Progress in Clinical Biochemistry and Medicine (Clarke MJ ed) pp 25-39, Springer-Verlag, Berlin.
8. Clarke MJ, Galang RD, Rodriguez VM, Kumar R, Pell S, and Bryan DM (1988) Chemical considerations in the design of ruthenium anticancer agents, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (Nicolini M ed) pp 582-601, Martinus Nijhoff, Boston.
9. Crissman HA and Steinkamp JA (1973) Rapid simultaneous measurement of DNA, protein and cell volume in single cells from large mammalian populations. J Cell Biol 59:766-771.
10. Farrell N, Qu Y, and Roberts JD (1999) Chemistry and biology of multifunctional DNA binding agents, in Metallopharmaceuticals I. Topics in Biological and Inorganic Chemistry (Clarke MJ and Sadler PJ eds) vol 1, pp 99-115, Springer, Berlin.
11. Galeano A, Berger MR, and Keppler BK (1992) Antitumor activity of some ruthenium derivatives in human colon cancer cell lines in vitro. Arzneim-Forsch 42:821-824.
12. Gelasco A and Lippard SJ (1999) Anticancer activity of cisplatin and related complexes, in Metallopharmaceuticals I. Topics in Biological and Inorganic Chemistry (Clarke MJ and Sadler PJ eds) vol 1, pp 1-43, Springer, Berlin.
13. 2SO-S)(Him)]. J Chem Soc Dalton Trans 3361-3371.
14. Keppler BK, Balzer W, and Seifried V (1987) Synthesis and antitumor activity of triazolium-bis(triazole)-tetrachloraruthenate (III) and bistriazolium-triazolepenta-chlororuthenate (III). Two representatives of a new class of inorganic antitumor agents. Arzneim-Forsch 37:770-771.
15. Keppler BK and Rupp W (1986) Antitumor activity of imidazolium-bisimidazoletetrachlororuthenate (III). J Cancer Res Clin Oncol 111:166-168.
16. Kurki P, Ogata K, and Tan EMJ (1988) Monoclonal antibodies to proliferating cell nuclear antigen (PCNA)/cyclin as probes for proliferating cells by immunofluorescence microscopy and flow cytometry. J Immunol Methods 109:49-59.
17. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
18. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
19. Liu F, Stanton JJ, Wu Z, and Piwnica-Worms H (1997) The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol Cell Biol 17:571-583.
20. Michael WM and Newport J (1998) Coupling of mitosis to the completion of S phase through cdc34-mediated degradation of Wee1. Science (Wash DC) 282:1886-1889.
21. Miller SA, Dykes DD, and Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
22. Morgan DO (1995) Principles of CDK regulation. Nature (Lond) 374:131-133.
23. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
24. Nanni P, De Giovanni C, Lollini PL, Nicoletti G, and Prodi G (1983) TS/A: a new metastasising cell line from BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1:373-385.
25. Ohi R and Gould KL (1999) Regulating the onset of mitosis. Curr Opin Cell Biol 11:267-273.
26. Pintus G, Tadolini B, Posadino AM, Sanna B, Debidda M, Bennardini F, Sava G, and Ventura C (2002) Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A downregulates c-myc gene expression and endothelial cells proliferation. Eur J Biochem, 269:5861-5870.
27. kip1, a cyclin dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
28. 1/S transition. Cancer Surv 29:7-23.
29. Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E, and Mestroni G (1998) Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis 16:371-379.
30. 4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors. Anti-Cancer Drugs 10:129-138.
31. 4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metastasis 10:273-280.
32. Serli B, Iengo E, Gianferrara T, Zangrando E, and Alessio E (2001) Novel unsymmetrical Ru(III) and mixed-valence Ru(III)/Ru(II) dinuclear compounds related to the antimetastatic Ru(III) drug NAMI-A. Met-Based Drugs 8:9-18.
33. 2d(pGpG)]. Science (Wash DC) 230:412-417.
34. Sherman SE and Lippard SJ (1987) Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 87:1153-1181.
35. 1 Phase progression: cycling on cue. Cell 79:551-555.
36. 2/M arrest and skipping of mitosis in human prostate cell lines. Cancer Lett 138:121-130.
37. Takizawa CG and Morgan DO (2000) Control of mitosis by changes in the subcellular location of cyclin B1-CDK1 and Cdc25c. Curr Opin Cell Biol 12:658-665.
38. Tamura H and Arai T (1992) Determination of ruthenium in biological tissue by graphite furnace AAS after decomposition of the sample by tetramethylammonium hydroxide. Bunseki Kagaku 41:13-17.
39. 2 arrest. Biol Cell 91:665-674.
40. 2-M cell fraction and inhibition of matrigel invasion, may predict in vivo-selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 295:927-933.